Quantitative In situ mRNA measurement for Companion Diagnostics.
Channel: RNAscope
Date: 2013-01-25

"Quantitative In situ mRNA measurement for Companion Diagnostics."
-- Dr. David Rimm, Ph.D. | Yale University School of Medicine

Presented at AMP2012 Corporate Workshop Day, October 24th, Long Beach, CA.

Dr. David Rimm is Professor of Pathology, Director of Yale Pathology Tissue Services and Director of Translational Science in Pathology at the Yale University School of Medicine. He completed his MD‐PhD at Johns Hopkins
University Medical School, Pathology Residency at Yale and a Cytopathology Fellowship at the Medical College of Virginia. His research focuses on quantitative pathology using AQUA® technology invented in his lab with projects
related to predicting response to therapy in breast cancer, predicting recurrence or metastasis in melanoma and lung cancer, primary cell culture, circulating tumor cells and in situ miRNA and mRNA analysis. He is currently supported
by 11 grants from both public and private sources. He is an author of over 230 peer‐reviewed papers and 8 patents and was the scientific co‐founder of HistoRx, a digital pathology company and Metamark Genetics, a prognostic
determinant company.